PMID- 15555258
OWN - NLM
STAT- MEDLINE
DCOM- 20050607
LR  - 20161124
IS  - 0253-2727 (Print)
IS  - 0253-2727 (Linking)
VI  - 25
IP  - 8
DP  - 2004 Aug
TI  - [Mismatched hematopoietic stem cell transplantation using GIAC protocol: report 
      of 100 cases].
PG  - 453-7
AB  - OBJECTIVE: To explore the clinical application of human leukocyte antigen (HLA) 
      mismatched hematopoietic stem cell transplantation (HSCT) for malignant 
      hematological diseases using a new GIAC protocol. METHODS: One hundred patients 
      with malignant hematological disease received G-CSF mobilization, intensive 
      immunosuppression, ATG and combination of bone marrow and peripheral blood stem 
      cell transplantation at least 1 locus mis-matched hematopoietic stem cell 
      transplant performed with GIAC protocol. The conditioning regimen was intensified 
      and prolonged with combined use of CsA, MMF and ATG for GVHD prophylaxis. 
      RESULTS: All patients achieved sustained, full donor-type engraftment. The 
      cumulative incidence of grade II approximately IV aGVHD was 48.39%, and grade III 
      approximately IV aGVHD was 12.90%. Thirty-eight patients had cGVHDs which were of 
      extensive type in 11 patients. Twelve patients relapsed, 11 of them were 
      high-risk patients, and 3 returned to CR after donor lymphocyte infusion. 
      Twenty-two patients died, owing to recurrent diseases in 6 and transplant-related 
      complications in 16 cases. Seventy-two patients were alive and disease free, with 
      1 year disease-free survival probabilities for standard and high risk patients of 
      (83.52 +/- 7.41)% and (47.63 +/- 8.49)%, respectively. CONCLUSION: The GIAC 
      protocol for at least 1 locus mismatched hematopoietic stem cell transplantation 
      is relatively safe and efficient for patients with hematological malignancies.
FAU - Han, Wei
AU  - Han W
AD  - Institute of Hematology, People's Hospital, Peking University, Beijing 100044, 
      China.
FAU - Lu, Dao-pei
AU  - Lu DP
FAU - Huang, Xiao-jun
AU  - Huang XJ
FAU - Liu, Kai-yan
AU  - Liu KY
FAU - Chen, Huan
AU  - Chen H
FAU - Xu, Lan-ping
AU  - Xu LP
FAU - Liu, Dai-hong
AU  - Liu DH
FAU - Jiang, Qian
AU  - Jiang Q
FAU - Chen, Yu-hong
AU  - Chen YH
FAU - Lu, Jin
AU  - Lu J
FAU - Wang, Jing-bo
AU  - Wang JB
FAU - Wu, Tong
AU  - Wu T
FAU - Dong, Lu-jia
AU  - Dong LJ
FAU - Ren, Han-yun
AU  - Ren HY
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Immunosuppressive Agents)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - HU9DX48N0T (Mycophenolic Acid)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antilymphocyte Serum/administration & dosage
MH  - *Bone Marrow Transplantation
MH  - Child
MH  - Child, Preschool
MH  - Cyclosporine/administration & dosage
MH  - Female
MH  - Graft vs Host Disease/*prevention & control
MH  - Granulocyte Colony-Stimulating Factor/therapeutic use
MH  - Hematopoietic Stem Cell Mobilization/methods
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Leukemia, Myeloid, Acute/mortality/therapy
MH  - Male
MH  - Methotrexate/administration & dosage
MH  - Middle Aged
MH  - Mycophenolic Acid/administration & dosage/*analogs & derivatives
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality/*therapy
MH  - Transplantation, Homologous
EDAT- 2004/11/24 09:00
MHDA- 2005/06/09 09:00
CRDT- 2004/11/24 09:00
PHST- 2004/11/24 09:00 [pubmed]
PHST- 2005/06/09 09:00 [medline]
PHST- 2004/11/24 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2004 Aug;25(8):453-7.